[go: up one dir, main page]

HK1202870A1 - 活性的改善的調控劑及其方法 - Google Patents

活性的改善的調控劑及其方法

Info

Publication number
HK1202870A1
HK1202870A1 HK15103447.6A HK15103447A HK1202870A1 HK 1202870 A1 HK1202870 A1 HK 1202870A1 HK 15103447 A HK15103447 A HK 15103447A HK 1202870 A1 HK1202870 A1 HK 1202870A1
Authority
HK
Hong Kong
Prior art keywords
hec1
activity
methods therefor
improved modulators
modulators
Prior art date
Application number
HK15103447.6A
Other languages
English (en)
Inventor
Yu-Ling Huang
Shih-Hsien Chuang
Ying-Shuan Eda Lee
Jiann-Jyh Huang
Johnson Lau
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of HK1202870A1 publication Critical patent/HK1202870A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
HK15103447.6A 2011-11-29 2015-04-22 活性的改善的調控劑及其方法 HK1202870A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564773P 2011-11-29 2011-11-29
PCT/US2012/067132 WO2013082324A1 (en) 2011-11-29 2012-11-29 Improved modulators of hec1 activity and methods therefor

Publications (1)

Publication Number Publication Date
HK1202870A1 true HK1202870A1 (zh) 2015-10-09

Family

ID=48536070

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103447.6A HK1202870A1 (zh) 2011-11-29 2015-04-22 活性的改善的調控劑及其方法

Country Status (12)

Country Link
US (2) US8999983B2 (zh)
EP (1) EP2785714B1 (zh)
JP (1) JP5970554B2 (zh)
KR (1) KR101983585B1 (zh)
CN (1) CN104254534B (zh)
AU (1) AU2012345843B2 (zh)
ES (1) ES2712134T3 (zh)
HK (1) HK1202870A1 (zh)
MX (1) MX371378B (zh)
SG (1) SG11201402144WA (zh)
TW (1) TWI640519B (zh)
WO (1) WO2013082324A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
CN113243374B (zh) 2012-10-02 2022-04-26 拜耳农作物科学股份公司 作为杀虫剂的杂环化合物
CA2929502A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors
CN106661624B (zh) * 2014-05-17 2021-04-06 加利福尼亚大学董事会 用于癌症诊断、预后和治疗选择的着丝粒/动粒蛋白基因
WO2019169135A1 (en) 2018-02-28 2019-09-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228175A (ja) * 1987-12-14 1990-01-30 Sawai Seiyaku Kk チアゾール環およびテトラゾール環を有するカルボキシアミド誘導体およびその用途
AU5135998A (en) * 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
DE60027034T2 (de) * 1999-10-22 2006-11-09 Takeda Pharmaceutical Co. Ltd. 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
AU2003250831A1 (en) 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
AU2004272599A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
EP3219709B1 (en) * 2004-01-30 2020-03-18 Vertex Pharmaceuticals Incorporated Intermediate compound of modulators of atp-binding cassette transporters
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
SI2404919T1 (sl) * 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
WO2007070600A2 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
US9090699B2 (en) 2006-05-02 2015-07-28 J. Suzanne Lindsey Mig-7 as a specific anticancer target
WO2009091813A1 (en) * 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
US20120108614A1 (en) * 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
BRPI1009372A2 (pt) * 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
EP2547676B1 (en) * 2010-03-17 2015-07-29 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
CN104395752B (zh) * 2011-11-21 2017-09-15 泰纬生命科技股份有限公司 对hec1活性调节剂具有反应的癌症的生物标记

Also Published As

Publication number Publication date
SG11201402144WA (en) 2014-09-26
EP2785714A4 (en) 2015-09-09
JP5970554B2 (ja) 2016-08-17
TWI640519B (zh) 2018-11-11
US20150250794A1 (en) 2015-09-10
EP2785714B1 (en) 2018-11-21
TW201326164A (zh) 2013-07-01
CN104254534A (zh) 2014-12-31
AU2012345843A1 (en) 2014-05-29
MX2014006157A (es) 2015-04-08
EP2785714A1 (en) 2014-10-08
NZ624552A (en) 2015-06-26
AU2012345843B2 (en) 2017-11-23
KR20140138596A (ko) 2014-12-04
CN104254534B (zh) 2017-07-14
MX371378B (es) 2020-01-28
WO2013082324A1 (en) 2013-06-06
ES2712134T3 (es) 2019-05-09
US8999983B2 (en) 2015-04-07
KR101983585B1 (ko) 2019-05-29
US10588909B2 (en) 2020-03-17
US20130190312A1 (en) 2013-07-25
JP2014534271A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
IL263020A (en) New modulators and methods of use
IL247595A0 (en) New modulators and methods of use
HK1215284A1 (zh) 位點特異性酶和使用方法
HK1176055A1 (zh) 活動的調製器及其調製方法
GB2488674B (en) Catalyst and method of preparation
IL227333A0 (en) A method for preparing lycosphingolipids and their uses
HK1199892A1 (zh) 經修飾的微型鐵調素肽及其使用方法
SG10201601792UA (en) Novel modulators and methods of use
PT3636274T (pt) Composições para modular a atividade das citocinas gama-c
IL225941A0 (en) Methods to increase the intracellular activity of @@@hsp
SG11201403276TA (en) Modified microorganisms and methods of making butadiene using same
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG10201506782XA (en) Notum protein modulators and methods of use
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1202870A1 (zh) 活性的改善的調控劑及其方法
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
PL2782670T3 (pl) Katalizator miedziowo-cyrkonowy oraz sposób stosowania i wytwarzania
AP2013007019A0 (en) Gaming system and method of use
EP2898044A4 (en) SOLID HYDROGEL MEDIA AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB2516380B (en) Catalyst and method of preparation
GB201316230D0 (en) Catalysts and methods of making and using catalysts
AU2011901049A0 (en) Catalysts and Methods of Use
GB201216724D0 (en) Note pad and method of use thereof
AU2012905377A0 (en) Bioreactor and method of use
GB201119022D0 (en) Use of CD1d ligands and hydrolases thereof